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Objective: Our goal was to test the recombinant human type II collagen (rhCII) material as a gel-like
scaffold for chondrocytes in a nude mouse model in vivo.
Design: Isolated bovine chondrocytes (6 106) were seeded into rhCII gels (rhCII-cell) and injected
subcutaneously into the backs of nude mice. For comparison, chondrocytes (6 106) in culture medium
(Med-cell) and cell-free rhCII gels (rhCII-gel) were similarly injected (n¼ 24 animals, total of three
injections/animal). After 6 weeks, the tissue constructs were harvested and analyzed.
Results: Chondrocytes with or without rhCII-gel produced white resilient tissue, which in histological
sections had chondrocytes in lacunae-like structures. Extracellular matrix stained heavily with toluidine
blue stain and had strongly positive collagen type II immunostaining. The tissue did not show any
evidence of vascular invasion or mineralization. The cell-free rhCII-gel constructs showed no signs of
cartilage tissue formation. Cartilage tissue produced by Med-cell was thin and macroscopically uneven,
while the rhCII-cell construct was smooth and rounded piece of neotissue. RhCII-cell constructs were
statistically thicker than Med-cell ones. However, no statistical differences were found between the
groups in terms of glycosaminoglycan (GAG) content or biomechanical properties.
Conclusions: These results show that rhCII-gel provides good expansion and mechanical support for the
formation of cartilage neotissue. RhCII material may allow favorable conditions in the repair of chondral
lesions.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Lesions in articular cartilage can cause severe pain, and they
often lead to osteoarthritis (OA) when left untreated1. Accordingly,
a number of methods have been developed to repair cartilage
defects. These include microfracture surgery2, or transplantation of
osteochondral plugs3. Although these methods have been used for
small cartilage lesions with encouraging clinical results, they may
cause signiﬁcant associated morbidity or ﬁbrous type of repair
tissue, especially when large defects have been treated. Autologous
chondrocyte transplantation (ACT) is a cell-based surgical methodHertta Pulkkinen, University
iomedicine, Anatomy, P.O.B.
ax: 358-17-163032.
inen).
s Research Society International. Pwhere isolated chondrocytes are transferred into the cartilage
defect and covered with a periosteal ﬂap4.
Novel techniques for cartilage repair aim to take the advantage of
bioresorbable scaffold materials in combination with autologous
chondrocytes5,6. A cell-friendly, biodegradable, and simultaneously
mechanically stiff, three-dimensional material with cell growth
enhancing properties would be an optimal scaffold for chon-
drocytes7. This would improve the ﬁlling of the lesion site, and help
the attachment of the repair tissue to the adjacent tissue. Currently,
a large variety of natural and synthetic polymers with different
compositions are under investigation, and also clinically used as
scaffolds for chondrocytes8e11. However, convincing long-term
clinical results from these newmaterials are still lacking and further
studies are needed to assure the reliability and predictability of the
materials toproducenormal andhealthy repair tissue7. As collagen is
the major matrix component in the articular cartilage, it is consid-
ered to be a favorablematerial for cartilage tissue engineering. It hasublished by Elsevier Ltd. All rights reserved.
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a ﬁbroblastic morphology, whereas cells in type II collagen retain
their chondrocytic features and high biosynthetic activity12.
However, due to its better availability, type I collagen has been often
used in different modiﬁcations. Soft scaffolds with the collagens in
a gel-like formula have also been under investigation13e16. Although
it is obvious that the mechanical properties of soft gels are not
comparable to stiffer materials, or native articular cartilage, the soft
formula offers several desirable qualities, such as the ﬂexible
composition of the gels, a goodﬂowof nutrients and sufﬁcient space
for cell proliferation and matrix production. The use of gels also
enables an injectable delivery of cells and biomaterial17.
Immune-deﬁcient nude mice have been used for various
purposes in cartilage research. They were ﬁrst used when chon-
drocytes from rabbits and dogs were injected subcutaneously18.
Since then, nude mouse animals have become a commonly used
model for designing matrices for cartilage reconstruction19,20, e.g.,
to test in vivo chondrogenic cell differentiation and cartilage
formation21,22. Injectable chondrocyte suspension in ﬁbrin gel
polymer formed newly synthesized cartilage, i.e., neocartilage
when injected subcutaneously, while ﬁbrin glue alone produced no
cartilage23. The same technique was used to compare how trans-
forming growth factor-b1 transfection affects human chon-
drocytes24. A nude mouse model has also been used to test the
chondrogenic differentiation of mesenchymal stem cells25,26.
The aim of our study was to use the nude mouse model to
investigate a new recombinant human (rh) type II (rhCII) collagen
biomaterial. Preliminary studies were done with recombinant
collagens types I and III in vitro in comparison with the type II. The
use of genetically modiﬁed microorganisms offers an effective way
of producing safe and non-animal-derived materials for tissue
engineering. Our previous results in vitro indicated that rhCII
material is a feasible scaffold for chondrocytes27.Fig. 1. Results from the preliminary study in vitro. The macroscopical appearance after 4 w
nostaining of rhCII gels immediately after gel preparation (B) and after 4 weeks of cultivatio
weeks in vitro cultivation of bovine chondrocytes within rh type I collagen (D), rhCII (E), anMethods
rh collagens
The rh collagens (types I, II and III) solubilized in HCl were
provided by Fibrogen Europe (Helsinki, Finland). Collagen solutions
were produced in yeast (Pichia pastoris) by recombinant tech-
nology, and then puriﬁed for further use. Recombinant strains of P.
pastoris have been shown to synthesize properly hydroxylated
triple helical recombinant collagen and, when coexpressed with
recombinant prolyl hydroxylase, to produce collagen with
a thermal stability similar to native collagens28.
Preliminary study in vitro with type I, II and III rh collagens
A preliminary study was conducted in vitro before nude mouse
experiments to choose the most suitable collagen for further
experiments [Fig. 1(A, DeF)]. Chondrocyte isolation, gel prepara-
tion, 4-week cultivation, and histological analyses were performed
as described previously27. Based on histological evaluation, rhCII
was selected for further studies in a nude mouse model in vivo.
Chondrocyte isolation
Articular cartilage was harvested from patellofemoral grooves of
18-month-old bovines (Atria abattoir, Kuopio, Finland). Chon-
drocytes were isolated from the cartilage slices in a two-step
isolation protocol performed at 37C and 5% CO2. Cartilage was
digested with 500 mg/ml of hyaluronidase (Sigma, St. Louis, MO,
USA) in Dulbecco’s modiﬁed medium (DMEM, Euroclone, Pero,
Italy) for 30 min. In the second digestion step, DMEM containing
300 mg/ml of collagenase (Sigma, St. Louis, MO, USA) and 200 mg/ml
of DNAase I (Sigma, St. Louis, MO, USA) was used overnight. Nexteeks in vitro cultivation of the rhCII gels (A). The bar¼ 5 mm. Type II collagen immu-
n in vitro (C), the bar¼ 70 mm. Safranin O stainings from the preliminary study after 4
d rh type III collagen gels (F). The bar¼ 400 mm (40 magniﬁcations).
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and suspended in DMEM into concentration of 1107 cells/ml of
medium. Cellular isolationwas performed similarly four times from
four different animals. After isolation, the viability of the cells was
examined using two ﬂuorescent probes, propidium iodide and
ﬂuorescein diacetate29.
Gel preparation and subcutaneous injections
Gels were made individually for each injection to guarantee
similar volume in all samples. rhCII solution (600 ml) was combined
with six million freshly isolated chondrocytes in growth medium
(600 ml) in anEppendorf tube. Themixturewas allowed to gel in 37C
for 1 h. After gelling, the excessive liquid was removed with centri-
fugation. At the same time, rhCII gels without cells were made by
combining rhCII solution (600 ml) andgrowthmedium(600 ml). After
removal of liquid, the volume used for injections was 400 ml/injec-
tion. For thescaffold-freecontrols, sixmillioncells ingrowthmediumFig. 2. The photograph A shows the location of injection sites of (1) rhCII-gel without cells (r
in growth medium (Med-cell). The subcutaneous injections were carried out on anesthet
implantation. A closer macroscopic view of the rhCII-cell construct (D) and Med-cell (E) afwere centrifuged to the same volume (400 ml). Before injection, the
viability of the chondrocytes in the gels was tested as previously
described29 fromextra gelsmade for this purpose. Experimentswere
carried onwhen cell viability was greater than 90%.
Nude mice were anaesthetized with 2e4% isoﬂurane (1-chloro-
2,2,2-triﬂuoroethyl diﬂuoromethyl ether, Isoﬂuran Baxter, Baxter,
Lessines, Belgium) before injection. Each mouse (n¼ 24) was
treated with three subcutaneous injections [Fig. 2(A)]: (1) cell-free
rhCII gels (rhCII-gel); (2) bovine chondrocytes in rhCII-gel (rhCII-
cell); and (3) bovine chondrocytes in growth medium (Med-cell).
The injection sites were located in the back of the mice, laterally to
the median plane of the animal in a triangular pattern [Fig. 2(A)].
Nomajor scar formation or skin abnormalities were detected in the
injection sites, and the animals behaved normally. After 6 weeks,
the animals were euthanized with CO2, and the constructs and
blood samples were collected for further analyses. The Institutional
Animal Care and Use Committee of the University of Kuopio and the
Provincial Government approved these animal experiments.hCII-gel); (2) bovine chondrocytes in rhCII-gel (rhCII-cell); and (3) bovine chondrocytes
ized mice (A). Implantation sites of rhCII-gel (B) and rhCII-cell (C) 6 weeks after the
ter 6 weeks. The bar¼ 5 mm.
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cate injections and divided into further analyses. The total number
of individual specimens was 7e12 in the analyses. Samples from
rhCII-gel injections could not be used for further analyses, since no
tissue formation was observed in the implantation sites.
Blood samples
Blood samples were collected from the mice at the time of
euthanization. The values of leukocytes, erythrocytes, hemoglobin
and thrombocytes were analyzed with an automated hematology
analyzer (Cell Dyn 3500R, Abbott Laboratories, Abbott Park, IL),
which has been shown to be a reliable and accurate instrument for
murine blood analysis30. Blood of the animals injected with rhCII
(n¼ 12) was compared to that of the non-injected control animals
of the same age (n¼ 10).
Histological analyses
Formaldehyde-ﬁxed constructs (n¼ 12 for Med-cell and rhCII-
cell) were embedded in Tissue-Tek III embedding wax (Sakura
Finetek Europe, Zoeterwoude, Holland) and cut into 5-mm thick
sections. Proteoglycans were stainedwith toluidine blue or safranin
O, and bone with Masson’s trichrome staining. Immunohisto-
chemical staining was performed with anti-type II collagen mouse
monoclonal antibody E831, which recognizes bovine and murine
type II collagens32. Type X collagen was immunostained with
mouse monoclonal antibody X5333 (Quartett, Berlin, Germany)
with overnight incubation (1:500) at 4C34. Anti-type I collagen
(Abcam, Cambridge, UK) was used with overnight incubation
(1:100) at 4C, after 20 min pepsin and 1 h hyaluronidase treatment
at 37C. For the immunostainings, negative control [1% bovine
serum albumin (BSA) in PBS] was included. For detection, Envi-
sionþ System-HRP (Dako, Glostrup, Denmark) was used. Alkaline
phosphatase (ALP) activity was demonstrated by 2 h incubation in
ALP substrate solution (0.2 mg/ml Naphtol AS-MX and 0.4 mg/ml
Fast Red TR in 100 mM Trisemaleate buffer, pH 9.2) after overnight
incubationwith MgCl2 (1% in Trisemaleate buffer, pH 9.2)35. Mouse
embryo and bovine cartilage were used as positive and negative
controls.
To analyze cellularity of the rhCII-cell and Med-cell constructs
the sections were stained with hematoxylin, the mounted glasses
were photographed, and the number of nuclei/mm2 was counted
with ImageJ 1.36b software (National Institute of Health, USA).
Enhanced polarized light microscopy
The specimens (n¼ 12 for both Med-cell and rhCII-cell) were
ﬁxed in neutral phosphate-buffered 10% formalin, and prepared for
the polarized light microscopic analysis as previously described36.
Sections (5-mm thick) from the middle part of the sample were cut,
dewaxed in xylene, and rehydrated. Tissue glycosaminoglycans
(GAGs) were digested with testicular hyaluronidase. The sections
were left unstained, embedded in DPX mounting medium (Difco,
East Molesey, UK), and examined with a computerized Leitz-
Ortholux POL microscope using 6.23 mm spatial resolution. The
degree of parallelism of the collagen network, i.e., the parallelism
index, and the absolute construct area were determined37.
Fourier-transformed infrared imaging
The 5-mm thick sections were prepared similarly to those used
for polarized light microscopy, and transferred to infrared-trans-
parent ZnSe-windows. Fourier-transformed infrared imaging
spectroscopy (FT-IRIS) was utilized to determine the amideabsorbance of the sections as a measure of collagen content38. The
nominal spatial resolution of Spectrum Spotlight FTIR imaging
system (Perkin Elmer, Cambridge, UK) was set to 6.25 mm, corre-
sponding to the pixel size in use. The absolute specimen reference
area was measured from amide spectrograms (mm2). Mean amide
absorbance values (per mm2) were calculated with IPLab software
(BD Biosciences, Rockville, MD, USA).
Biochemical analyses
The constructs were divided into two sample sets, one for the
quantitative analysis of proteoglycans and one for the structural
proteoglycan analysis by agarose gel electrophoresis. For quanti-
tative analysis, the wet weights of the samples (n¼ 11 for both
groups: Med-cell and rhCII-cell) were measured. The samples were
freeze-dried and weighted before further processing with papain
digestion27. The uronic acid contents of the digests were quantiﬁed
from the ethanol-precipitated samples39. The uronic acid content
was normalized by the wet weight of the sample. The other set of
specimens was extracted with 4 M guanidinium HCl in (GueHCl)
50 mM sodium acetate, pH 5.8, supplemented with 10 mM diso-
dium EDTA, 5 mM benzaminide HCl and 100 mM 6-aminohexanoic
acid for 48 h. For agarose gel electrophoretic analysis of proteo-
glycan subpopulations, the samples were precipitated with 75%
ethanol. The precipitated samples (1 mg of uronic acid) were dis-
solved in 7 ml of sample buffer (1% SDS in 40 mM Triseacetate and
1 mM sodium sulfate, pH 6.8), boiled for 5 min, and 7 ml of 60%
sucrose and 0.05% bromphenol blue in sample buffer was added to
the samples. The electrophoresis in 1.2% agarose was performed in
40 mM Triseacetate and 1 mM sodium sulfate, pH 6.8, for 3 h at
60e80 mA and 40 V. After electrophoresis, the gel was ﬁxed for 2 h
in methanol:acetic acid:water (50:7:43, v:v:v) mixture, and stained
with 0.02% toluidine blue in 3% acetic acid for 4 h. Excessive stain
was removed by 3% acetic acid, and the gel was scanned. Bovine
articular cartilage (GueHCl and papain extracted), mouse skin
(GueHCl extracted) and chondroitin sulfate C (Sigma) were treated
similarly as positive and negative controls.
Mechanical testing
For analysis of the mechanical properties of the rhCII-cell
(n¼ 10) and Med-cell (n¼ 7) constructs the samples were cut with
a 3 mm biopsy punch (Kai Industries, Oyana, Gifu, Japan) prior to
testing. The cutting was performed to minimize changes in the
sample shapes. A material testing device was used to analyze
dynamic and equilibrium (Young’s) modulus and the thickness of
the cylindrical samples40.
Statistical analysis
Statistical comparisons between the groups, i.e., rhCII-cell and
Med-cell,weremadeusingManneWhitneyU test (for the cellularity,
uronic acid, dynamic thickness andYoung’smodulus).P-value< 0.05
was set as a limit for statistical signiﬁcance for all tests.
Results
Preliminary study in vitro with rh type I, II and III collagens
The in vitro cultivated chondrocyte-seeded rhCII gels [Fig. 1(A)]
showed increased immunostaining for collagen type II during the
cultivation from day 0 [Fig. 1(B)] to day 28 [Fig. 1(C)]. Proteoglycan
staining with safranin O41 showed the highest intensity for rhCII
gels [Fig. 1(E)] compared with rh type I [Fig. 1(D)] and rh type III
[Fig. 1(F)] collagens. Since type II collagen is also the major
Table I
Blood analyses
Mouse Blood count
Leukocytes (103/ml) Erythrocytes (103/ml) Hemoglobin (g/dl) Hematocrit (%) Thrombocytes (103/ml)
Non-treated 95% CI 2.95 (1.77, 3.81) 9.26 (9.03, 9.48) 148.00 (144.77, 151.23) 0.46 (0.45, 0.47) 673.95 (490.03, 857.87)
Gel implanted 95% CI 2.79 (2.07, 3.82) 9.29 (8.99, 9.58) 147.80 (143.24, 152.36) 0.46 (0.45, 0.48) 667.30 (432.15, 962.45)
P-value 0.947 0.817 0.842 0.428 1.000
The values of leukocytes, erythrocytes, hemoglobin, hematocrit and thrombocytes in blood were analyzed after 6 weeks of injection of rhCII-gel and chondrocytes under the
skin of nudemouse (n¼ 12). Control samples were taken from non-treatedmice (n¼ 10). Values indicate themean and 95% conﬁdence intervals (95% CIs) of the results (lower
limit, upper limit).
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with rhCII gels.Blood samples
Analysis of blood samples was performed to detect possible
adverse effects of the rhCII material in the mice. No differences
were detected between the control animals and themice with rhCII
constructs placed under their skin in terms of leukocytes, eryth-
rocytes, thrombocytes, hemoglobin, and hematocrit (Table I).Macroscopical appearance and properties
After 6 weeks of implantation in a nude mouse, the rhCII-gel
without cells had mostly dissolved, and only a barely detectable
thin layer of material remained at the location of injection [Fig. 2
(B)]. The chondrocytes within rhCII-cell produced a round to oval
piece of whitish, translucent and resilient tissue [Fig. 2(C) and (D)].
The cells of Med-cell also formed a piece of white tissue, but the
appearance was thin, uneven and rough [Fig. 2(E)]. No macroscopic
signs of vascular invasion or abnormal growth of connective tissue
were detected around the constructs. The thickness measurement
using a mechanical testing device revealed that the rhCII-cell
constructs were two times thicker than the ﬂattened Med-cell
constructs (Table II). Because rhCII-gel formed no tissue, it was no
further analyzed.Histological analyses
The chondrogenic character of the tissue constructs was
examined with toluidine blue stainings (Fig. 3). After 6 weeks’
cultivation in vivo, rhCII-cell produced tissue that was heavily
stained with cationic dye toluidine blue [Fig. 3(A)], indicating the
presence of abundant extracellular matrix proteoglycans. Chon-
drocytes had also formed lacunae-like structures [Fig. 3(B)]. TheTable II
Cellularity (cells/mm2), uronic acid (mg/mg wet weight), dynamic modulus (MPa)
and Young’s modulus (MPa) of the constructs
RhCII-cell
construct
Med-cell
construct
P-value
Cellularity
(cells/mm2)
565 (493, 636)
(n¼ 10)
528 (421, 635)
(n¼ 8)
0.398
Uronic acid
(mg/mg wet weight)
0.88 (0.46, 1.30)
(n¼ 11)
0.99 (0.35, 1.62)
(n¼ 11)
0.944
Thickness of the
construct (mm)
701 (550, 853)
(n¼ 10)
337 (205, 468)
(n¼ 7)
0.003*
Dynamic modulus
(MPa)
0.18 (0.75, 0.28)
(n¼ 10)
0.20 (0.12, 0.28)
(n¼ 7)
0.242
Young’s modulus
(MPa)
0.08 (0.01, 0.17)
(n¼ 10)
0.12 (0.04, 0.21)
(n¼ 7)
0.230
Values indicate the mean and 95% CIs (lower limit, upper limit) of the results.
Statistically signiﬁcant difference (*) was noticed in the thickness of the constructs.ﬁndings in Med-cell were similar, except that the constructs were
more condensed than the rhCII-cell construct [Fig. 3(C) and (D)].
Collagen type II immunostaining was strongly positive in both
rhCII-cell [Fig. 3(E)] and Med-cell [Fig. 3(F)] constructs. The Med-
cell construct was surrounded by type II-negative connective
tissue. Negative controls stained with normal murine serum
showed no or only faint staining of the respective tissue sections
[Fig. 3(G) and (H)]. Type I collagen immunostaining revealed that
type I collagenwas also present in the constructs [Fig. 4(A) and (B)].
Bone tissue in mouse embryo was used as a positive control [Fig. 4
(C)].
The stainings for hypertrophic or mineralizing cartilage markers
(type X collagen and ALP activity) showed negative results in rhCII-
cell and Med-cell samples, while staining in the positive controls
was observed [Fig. 5(AeF)]. Masson’s trichrome staining indicated
that the ectopic cartilage implants stained with blue, as did the
normal bovine cartilage [Fig. 5(GeI)]. The cellularity analysis
revealed no differences between the rhCII-cell gel and Med-cell
constructs (Table II).
Biochemical analyses
The dry weight of tissue constructs produced by the rhCII-cell
and Med-cell were 1.10 0.33 mg (n¼ 11), and 1.36 0.82 mg
(n¼ 11), respectively. On the basis of similar uronic acid concen-
trations no detectable differences in GAG content were evident
between the groups (Table II). Agarose gel electrophoretic analysis
[Fig. 6(G)] revealed that in both construct groups the proteoglycans
were primarily large proteoglycans with the mobility typical of
aggrecan molecules, while the amount of small proteoglycans
(relative mobility of approximately 0.85e0.90 in proportion to the
bromphenol blue front) was low, consistent with previous litera-
ture42,43. The mobility of bovine articular cartilage proteoglycans
was similar to rhCII-cell and Med-cell. Chondroitin sulfate C and
papain-digested cartilage had faster mobility than small proteo-
glycan population [Fig. 6(G)]. No proteoglycan bands were seen
from the mouse skin sample extract (data not shown).
FT-IRIS analysis and polarized light microscopy
The content of collagen was estimated by FT-IRIS analysis. The
mean amide absorbance per pixel (representing the collagen
content) was 0.50103 0.27103 units/mm2 in the rhCII-cell
group and 0.43103 0.13103 units/mm2 in theMed-cell group.
The average area of constructs did not differ either between the two
groups (3.041061.61106 mm2 vs 2.731061.28 106 mm2).
However, Med-cell constructs [Fig. 6(E)] appeared to have higher
variation in the local collagen content than rhCII-cell ones [Fig. 6(B)].
This can be related to more heterogeneous structure of Med-cell
shownby toluidine blue-stained sections from the same region [Fig. 6
(D) vs Fig. 6(A)]. Polarized light microscopy analysis was used to
evaluate the arrangement of collagen network of the constructs. The
parallelism index was 0.32 0.07 (mean SD) in the Med-cell and
Fig. 3. Toluidine blue stainings showing extracellular matrix 6 weeks after subcutaneous injections. The chondrocytes seeded in rhCII (rhCII-cell) (A). A higher magniﬁcation of
the rhCII construct (B). The chondrocytes in growth medium (Med-cell) (C). A higher magniﬁcation of the Med-cell construct (D). The bar¼ 1000 mm (A and B, 40magniﬁcations),
the bar¼ 50 mm (C and D, 100 magniﬁcations).
Immunostaining for type II collagen showed a strong signal in cell-seeded rhCII constructs (rhCI-cell), particularly around the chondrocytes, suggesting accumulation of collagen
type II (E), while non-cartilaginous areas negative for type II collagen were visible in scaffold-free constructs (Med-cell) (F). Negative controls treated with BSA in rhCII (G) and
scaffold-free (H) constructs are shown. The bar¼ 50 mm (100 magniﬁcations).
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Fig. 4. Immunostaining for type I collagen with hematoxylin counterstaining in rhCII-cell (A) and Med-cell (B). A light red staining is detected through the specimens in both
samples. Developing bone (red staining indicated by arrow) in the mouse embryo was stained as a positive control (C). Negative controls treated with BSA for rhCII-cell (D), Med-cell
(E) and mouse embryo (F) are also shown. The bar¼ 100 mm (100 magniﬁcations).
H.J. Pulkkinen et al. / Osteoarthritis and Cartilage 18 (2010) 1077e1087 10830.37 0.10 in the rhCII-cell group. The same result can be seen
visually in polarized light microscopic images captured from Med-
cell [Fig. 6(F)] and rhCII-cell [Fig. 6(C)] constructs.
Mechanical testing
Mechanical testing of the constructs was performed to obtain
the Young’s modulus and the dynamic modulus of the constructs.
Although the macroscopic appearance of the tissue was different
between the rhCII-cell and Med-cell constructs, there were no
signiﬁcant differences in the Young’s or dynamicmodulus (Table II).
The mechanical stiffness did not fully reach that of bovine articular
cartilage44, but was higher than that obtained with in vitro
cultivation29.
Discussion
In the present study, we show that rhCII-gel with chondrocytes
(rhCII-cell) formed a tissue with abundant presence of collagen and
proteoglycans when grown for 6 weeks subcutaneously in the
backs of nude mice. The tissue formed during the 6-week cultiva-
tion resembled hyaline cartilage macroscopically and microscopi-
cally, although some staining for type I collagen was also observed.
Cartilage-looking tissue was produced also by chondrocytes alone
(Med-cell). Theoretically it is possible that the murine cells may
contribute to the formation of the neotissue. However, the absence
of cartilage formation in the cell-free rhCII-gel suggests that murine
cells do not have major role in the ectopic cartilage formation.
The major difference between the groups was the structure of
the constructs. Without scaffold, the resulting tissue was more
ﬂattened, and appeared to contain several layers of tissue, in
contrast to the smooth, oval and more regular appearance of the
rhCII-cell constructs. It appeared that the absence of scaffold
allowed chondrocytes to spread between the membranous struc-
tures under the skin. In rhCII-gel, notably a more uniform tissue
growth developed. The rhCII-cell constructs were also signiﬁcantly
thicker than the Med-cell. The beneﬁts of this cohesive feature will
become useful in practice when better ﬁlling of defects is desired.Isolated articular chondrocytes are often presumed to be at an
appropriate maturation stage to proliferate and also to differentiate
to some extent45. These properties are important in cartilage repair.
In this study we decided to use primary bovine chondrocytes to
provide the construct with an optimal cell source, although in
clinical applications the cells are usually expanded. Chondrocyte
hypertrophy and terminal differentiation are not desired, since they
lead to ossiﬁcation of the repair tissue. Here, the chondrocytes in
both construct types (rhCII-cell and Med-cell) expressed chon-
drocytic phenotype, and both produced lacunae-like formations
during the 6-week long growth period. A high content of extra-
cellular matrix proteoglycans was also detected. There were no
signs of hypertrophy in neither of the constructs. Similar ﬁndings
were detected in a previous study26, where it was noticed that
expanded articular chondrocytes did not hypertrophy in immu-
nocompromizedmice. However, when differentiatedmesenchymal
stem cell-derived pellets were grown scaffold-free in a mouse
model, the constructs underwent hypertrophy, had vascular inva-
sion and deposited minute ossicles in the model26. In a previous
study, basic ﬁbroblast growth factor was used to promote the
formation of vasculature around the construct46. In our study
cartilage formationwas evident without addition of growth factors,
similar to chondrocytes cultured on ﬁbrous synthetic materials47.
The chondrocytes maintained their capacity to produce extra-
cellular matrix during the cultivation, indicated by the intense
toluidine blue staining in both construct types. The proteoglycan
staining and the intense pericellular immunostaining for type II
collagen make it likely that the implanted chondrocytes produced
also type II collagen. In our previous data in vitro27 we could notice
an increase in the matrix production in the rhCII-cell constructs
cultivated for 4 weeks in cell culture conditions. In the present
analysis in vivo, a much higher level of staining of the matrix was
detected in the histological specimens after 6 weeks in vivo. Also
the mechanical stiffness was remarkably different in these studies.
When the rhCII-cell constructs were cultivated in vitro, the speci-
mens were getting harder during the cultivation time but never got
stiff enough to be mechanically analyzed (unpublished data).
However, in the in vivo nude mouse model we could gain
Fig. 5. Type X collagen immunostaining in rhCII-cell (A), and Med-cell (B) with positive control indicating type X collagen in the hypertrophic cartilage in mouse embryo (C). ALP
enzymehistochemical staining in rhCII-cell constructs (D), and Med-cell constructs (E) and positive control showing hypertrophic cartilage in mouse embryo (F). Masson’s trichrome
staining of rhCII-cell (G), and Med-cell constructs (H). In the positive control bovine articular cartilage is stained blue and bone red (I). The bar¼ 100 mm (100 magniﬁcations).
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Consequently the mouse model offers a major improvement to the
cultivation environment and properties.
There was no difference between rhCII-cell and Med-cell in
terms of equilibrium and dynamic stiffness. Furthermore, the
mechanical stiffness of the constructs did not reach the level of
adult articular cartilage. It has been shown that the biomechanical
properties of bovine articular cartilage change during a long period
of maturation from fetal to calf to adult48. This process involves
maturation and crosslinking of the collagen network; this large
scale remodeling signiﬁcantly affects the functional properties of
the tissue49. Obviously, the present 6-week implantation period
was too short for the maturation of the constructs. Naturally, the
mechanical properties and other biological characteristics under
the skin do not exactly resemble the conditions in a normal joint.
Addition of crosslinking agents or stabilizers could have improved
the stiffness of the gels, but these were not used due to their
potential interference with the natural remodeling of the construct
material.
The impaired organization of the implant was most evident in
the polarized light microscopic analyses of the rhCII-cell and Med-
cell tissues. The polarization signal of both constructs differed
markedly from the one obtained from the normal articular carti-
lage, indicating that the collagen ﬁbers were not orientated as in
native cartilage. The collagen content appeared rather similar in
both implantation groups.
No signs of vascular invasion or increased vasculature were
detected around the neotissue constructs, but apparently bothrhCII-cell and Med-cell structures were able to receive sufﬁcient
nutrients and oxygen from the surrounding connective tissue,
and the use of rhCII-gel did not weaken the survival of the cells.
This is important, since it has been shown previously that
a biomaterial, although otherwise promising, can be lethal to the
cells if it does not allow even distribution of the cells, exchange
of essential molecules, or if the decomposing particles are
toxic50.
For clinical applications, it is advantageous to retain the
implant shape during the regeneration progress. In this study,
rhCII-cell constructs showed regular expansion and round shapes,
demonstrating the growth potential of the neotissue, whereas the
Med-cell constructs had a much more irregular and malformed
appearance. It has been shown in vitro that the chondrocyte-
seeded type I collagen gels contract remarkably during cultiva-
tion15. This was revealed also in rhCII-seeded gels in vitro27.
However, the contraction was not a particular problem in the nude
mouse model.
In conclusion, the use of animal-component free rhCII-gel as
a scaffold for chondrocytes promoted a better maintenance of
neotissue construct shape, compared with the cells without
a scaffold. The soft gel material without any synthetic or animal-
derived additives allows a safe and reproducible way of adding
more structural competence to the implantation of chondrocytes.
The results of this study indicate that the rhCII material might also
be used for other applications, such as in a replacement procedure
for nasal cartilages. By using external pre-shaped scaffolds,
a desired three-dimensional structure to shape the forming
Fig. 6. Toluidine blue-stained sections from rhCII-cell (A) and scaffold-free Med-cell (D) constructs are shown as a reference for FTIR-IS analysis (B and E, respectively). The
organization of collagen network, evaluated by parallelism, was evaluated by polarized light microscopy of the rhCII-cell (C) and Med-cell constructs (F). The color scale in B and E
indicates the content of collagen (blue is low and red high content), while the scale in C and F indicates the collagen parallelism (red is low and blue high degree of parallelism).
Scale bars are shown in the pictures.
Photograph G of agarose gel electrophoresis. Agarose gel electrophoresis of extracted proteoglycans shows the similarity in proteoglycan mobility of the rhCII-cell and Med-cell
constructs with bovine articular cartilage proteoglycans. Lane 1: rhCII-cell, lane 2: Med-cell, lane 3: bovine cartilage extract, lane 4: chondroitin sulfate C, lane 5: papain-digested
cartilage proteoglycans.
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structural properties, is potentially useful for cartilage tissue
engineering.
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